Catalyst
Slingshot members are tracking this event:
OCREVUS (ocrelizumab) for the treatment of RMS and PPMS, and has extended the application Priority Review Designation with a targeted action date of 28th March 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2017
Occurred Source:
http://www.roche.com/media/store/releases/med-cor-2017-03-29.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ocrelizumab, Priority Review Designation, Multiple Sclerosis, Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Ocrelizumab
